Silico Clinical Trials Market Size & Share Analysis

The new report published by The Business Research Company, titled In Silico Clinical Trials Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the in silico clinical trials market size has grown strongly in recent years. It will grow from $3.31 billion in 2023 to $3.59 billion in 2024 at a compound annual growth rate (CAGR) of 8.6%. The in silico clinical trials market size is expected to see strong growth in the next few years. It will grow to $5.02 billion in 2028 at a compound annual growth rate (CAGR) of 8.7%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12224&type=smp

Escalating Prevalence Of Chronic, Infectious, And Neurological Diseases Fuels Growth In The In Silico Clinical Trials Market
The rise in chronic, infectious, and neurological disease prevalence is expected to propel the growth of the in silico clinical trials market going forward. Chronic diseases are problems that last a year or longer, necessitating continuing medical care, restricting everyday activities, or both. Infectious disease is caused by a pathogen or its toxic byproduct that spreads to a susceptible host through contact with an infected human, animal, or inanimate object. Neurological disorders refer to illnesses that impact the spinal cord, the body's nerves, and the brain. The rise in chronic, infectious, and neurological disease prevalence increases the need for better medication and treatments. In silico trials are used for faster drug development to treat these diseases. For instance, in January 2023, according to the National Centre for Biotechnology Information (NCBI), a US-based National Library of Medicine, it was projected that by the year 2050, the number of individuals aged 50 years and older who have at least one chronic illness will surge by 99.5%, rising from 71.522 million in 2020 to 142.66 million. Furthermore, in May 2022, according to the World Health Organization, a Switzerland-based specialized health agency, compared to 245 million cases in 2020, there were 247 million cases of malaria in 2021. Compared to 625 000 in 2020, the expected number of malaria deaths was 619 000 in 2021. Furthermore, in December 2022, according to the Parkinson's Foundation report published by a US-based non-profit organization working for Parkinson's disease patients, the new diagnosis of Parkinson's disease reached 90,000 per year, increasing from 60,000 per year in 2021. Therefore, the rise in chronic, infectious, and neurological disease prevalence is propelling the growth of the in silico clinical trials market.

Partnerships Shape The Landscape Of The In Silico Clinical Trials Market
Strategic partnerships are a key trend gaining popularity in the in silico clinical trials market. Major companies operating in the in silico clinical trials market are undergoing partnerships to strengthen their position in the market. For instance, in March 2023, Premier Research, a US-based clinical research organization (CRO), partnered with InSilicoTrials, a US-based company providing modeling and simulation in drug development. This partnership enables Premier Research to create safer, faster, and more efficient pathways to get approval for rare disease treatments. Furthermore, in March 2022, 4P-Pharma, a France-based clinical-stage biotech company, partnered with QuantHealth, an Israel-based AI company, to conduct patient-centric drug simulations to accelerate and de-risk drug development. This partnership helps 4P-Pharma to perform in silico clinical trials of lead drug candidates and speed up clinical trial simulations based on deep molecular drug data and real-world data (RWD).

The in silico clinical trials market covered in this report is segmented -

1) By Phase: Phase I, Phase II, Phase III, Phase IV
2) By Therapeutic Area: Oncology, Infectious Disease, Hematology, Cardiology, Dermatology, Neurology, Diabetes, Other Therapeutic Areas
3) By Industry: Medical Devices, Pharmaceutical

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12224&type=discount

Major companies operating in the in silico clinical trials market report are Dassault Systemes SE, Clarivate plc, Evotec A.G, Evidera, Certara Inc., Abzena Limited, Selvita, Simulations Plus Inc., Insilico Medicine Inc., AnyLogic Company, Biomax Informatics, GNS Healthcare Inc., 4P-Pharma, Nuventra Pharma Sciences, Archimedes, Novadiscovery Sas, Rosa & Co., In Silico Biosciences, Leadscope, Biognos Ab, BioNova, Immunetrics Inc., InSilicoTrials, Physiomics plc, InhibOx, Entelos

Contents of the report:
1. Executive Summary
2. In Silico Clinical Trials Market Report Structure
3. In Silico Clinical Trials Market Trends And Strategies
4. In Silico Clinical Trials Market - Macro Economic Scenario
5. In Silico Clinical Trials Market Size And Growth
…..
27. In Silico Clinical Trials Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/in-silico-clinical-trials-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.